Enoximone (INN, trade name Perfan) is an imidazole phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure and is selective for phosphodiesterase 3.

Enoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption.

Enoximone is a phosphodiesterase type-3 inhibitor that exerts most effect on the myocardium; it has positive inotropic properties and vasodilator activity.

Enoximone (Perfan – Merrell) and milrinone (Primacor – Sterling-Winthrop) are phosphodiesterase inhibitors marketed for short-term intravenous use in patients with heart …

Enoximone is an imidazolone derivative currently undergoing trials in patients with congestive heart failure refractory to conventional therapy. It is a phosphodiesterase inhibitor with both …

PDE‐3 inhibitors, including amrinone, milrinone, and enoximone, inhibit the enzyme PDE‐3 with consequently increased concentrations of available cAMP and intracellular calcium. Milrinone …

Enoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients …

Enoximone is an imidazole derivative with selective PDE III inhibition. It is useful for the short-term support of cardiac output in patients with chronic heart failure, in whom elevated …

Oct 31, 2012 · Enoximone is an imidazolone derivative currently undergoing trials in patients with congestive heart failure refractory to conventional therapy. It is a phosphodiesterase inhibitor …

Amrinone, milrinone and enoximone are used clinically for short-term treatment of cardiac failure in the presence of cardiogenic shock. [1] PDE3 inhibitors are indicated as inotropics for the …